echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Graph showing how antibodies attack mutant spike proteins

    Graph showing how antibodies attack mutant spike proteins

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious disease experts are eager to know whether the new variant is resistant to the human antibodies that recognized the original version of the virus
    .
    COVID-19 vaccines developed based on the chemistry and genetic code of this initial virus may provide less protection if the antibodies they help people produce cannot resist new virus strains

    .
    Now, researchers and collaborators from Brigham and Women's Hospital have created a "map" that records how 152 different antibodies attack a major part of the new coronavirus mechanism-the spike protein.
    Protein has been evolving since 2020

    .
    Their research, published in the journal Cell, emphasized antibodies that can neutralize new strains, while identifying areas of the spike protein that are more resistant to attack

    .

    Corresponding author Duane Wesemann, MD, an associate professor in the Department of Allergy and Clinical Immunology and Genetics at Brigham University and an associate professor at Harvard Medical School, said: “Emerging data shows that vaccines can still be effective against new vaccines.
    The SARS-CoV-2 mutation provides some protection.
    Our research shows how this works from the perspective of antibodies

    .
    These data can help us think about how the best booster vaccine might be by studying how human antibodies recognize spike proteins What

    .
    "

    The researchers tested the antibody-producing memory B cells of 19 patients infected with SARS-CoV-2 in March 2020 before the emergence of the new mutation
    .
    They studied how these antibodies and other antibodies that the researchers have identified bind to the spike protein models of the SARS-CoV-2 variants B.
    1.
    1.
    7 (Alpha), B.
    1.
    351 (Beta) and P.
    1 (Gamma) , These variants were first discovered in the United Kingdom, South Africa and Brazil

    .
    The analysis of the currently popular delta variant is in progress

    .

    Overall, the authors confirmed that the hundreds of antibodies they studied primarily bind to seven major "footprints" on the spike protein
    .
    Although many antibodies "compete" to bind to the same region of the earlier version of the SARS-CoV-2 spike protein, when newer strains are involved, some antibodies lose their effectiveness, while others become neutralizing a broad response Agent

    .

    In particular, antibodies that bind to the two spike protein regions, called RBD-2 and NTD-1, are the most effective neutralizers in the original form of spike proteins
    .
    Facts have proved that the B.
    1.
    351 thorn mutant has the greatest ability to evade the existing antibody library, and can evade many RBD-2- and NTD-1 binding antibodies

    .
    Some antibodies bind to another region called S2-1, which can recognize spike proteins from more distantly related viruses (such as Middle East Respiratory Syndrome, SARS, and common cold coronavirus)

    .

    Wesemann said: "Making different antibodies to compete for a region of the virus can make the immune system more flexible
    .
    Otherwise, redundant recognition of antibodies against the same footprint of the same virus version provides the depth of recognition of the same footprint of the variant.
    Some antibodies Maintain high school and potency for all variants

    .
    Now that we can identify antibodies that respond more broadly to all variants, we can consider how to stimulate them more strongly in vaccines

    .
    "

    # # #

    Original search: Tong P et al.
    "Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike" Cell DOI: 10.
    1016/j.
    cell.
    2021.
    07.
    025

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.